CVX has pulled back to $199.77, down 2.9% on the week, as the $196–$200 support band flagged in Tuesday's note faces its sharpest test yet. Three separate data streams converged this week — but the signal worth focusing on is options, not short interest.
The put/call ratio hit 0.789 on August 25, a 2.5-sigma deviation above the 20-day mean of 0.683. It has since eased to 0.711, still elevated relative to the July base of roughly 0.62–0.63. The 52-week range runs from 0.596 to 0.960, so the current reading is not extreme in absolute terms — but the pace of the move matters. The PCR has climbed steadily since mid-August as CVX has struggled to hold $205.
Options traders are not making a high-conviction bear bet. They are hedging. The consensus analyst target of $218 sits 9% above current levels. The positioning gap between where analysts see fair value and where options traders are buying protection is the defining tension in CVX right now.
Short interest is down 23% over the past week to 0.78% of free float — near multi-month lows. This is an afterthought at that level. Borrow costs ticked up 73% week-on-week to 0.45%, but that number in isolation is misleading: 0.45% is still negligible, and availability remains essentially unconstrained. The cost move reflects lender supply adjustments, not any meaningful increase in bearish demand. Tuesday's note said the lending market had nothing interesting to add. That remains true today.
The insider picture has not changed since the August 19 note. CEO Mike Wirth sold $61.5 million worth of shares on August 14 and a further $2.1 million the same day, with another $1 million on August 5. The Chief Legal Officer sold $507K on August 18. Director John Hess — who joined the board following the Hess acquisition — sold over $42 million across four trades on August 3. Net insider sales over the past 90 days total $302 million. These look like planned distributions rather than a read on near-term direction, but the pattern of selling into every rally deserves to stay on the radar.
The $196–$200 band is the line. CVX held it through Tuesday's sector-wide pullback — XOM dropped 3%, APA fell 5.2% on the week — and CVX's 2.9% decline keeps it roughly in line with peers rather than leading them lower. October 30 earnings remain the next hard catalyst.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
